Earnings summaries and quarterly performance for Climb Bio.
Executive leadership at Climb Bio.
Board of directors at Climb Bio.
Research analysts covering Climb Bio.
Recent press releases and 8-K filings for CLYM.
Climb Bio Announces Pipeline Progress and Refreshed Financial Guidance
CLYM
Guidance Update
New Projects/Investments
- Climb Bio announced significant pipeline progress for its budoprutug and CLYM116 programs, including dosing the first patients in the budoprutug PrisMN Phase 2 trial and the CLYM116 Phase 1 healthy volunteer study, and achieving regulatory clearance for its Systemic Lupus Erythematosus (SLE) Investigational New Drug (IND) in China.
- The company anticipates a data-rich 2026, with initial readouts expected from all ongoing budoprutug and CLYM116 studies, including the budoprutug subcutaneous formulation Phase 1, PrisMN (pMN) Phase 2, ITP Phase 1b/2a, SLE Phase 1b, and CLYM116 Phase 1.
- Climb Bio refreshed its financial guidance, indicating a strong financial position with cash, cash equivalents, and marketable securities expected to fund operations into 2028.
Jan 8, 2026, 12:07 PM
Climb Bio Highlights Clinical Development and 2026 Data Readouts
CLYM
New Projects/Investments
Guidance Update
- Climb Bio is focused on developing differentiated monoclonal antibody (mAb) therapeutics for immune-mediated diseases, with key programs Budoprutug (anti-CD19 mAb) targeting primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE), and CLYM116 (anti-APRIL mAb) for IgA nephropathy (IgAN).
- The company anticipates a data-rich 2026 with initial clinical readouts from all ongoing trials, including Budoprutug in pMN, ITP, SLE, and its SC formulation, and CLYM116 in mid-2026.
- Climb Bio is well-resourced to advance its clinical programs, with its financial runway anticipated into 2028.
- In a completed Phase 1b study for pMN, Budoprutug demonstrated 100% serologic remission (anti-PLA2R negativity) and 100% complete or partial clinical remission.
Jan 8, 2026, 12:00 PM
Climb Bio Files Lawsuit Over Disputed Milestone Payment
CLYM
Legal Proceedings
New Projects/Investments
- Climb Bio, Inc. (CLYM) initiated legal proceedings on December 31, 2025, against Alumis Inc. and its subsidiary Acelyrin, Inc., concerning an Asset Purchase Agreement (APA) dated January 11, 2024, related to the budoprutug drug candidate.
- Climb seeks a declaratory judgment that its budoprutug drug candidate is not a "Product" under the APA, asserting that no "Royalty-Bearing Patents" exist, which are required to trigger future payment obligations.
- The dispute specifically involves a $3 million milestone payment invoiced by Alumis, due January 1, 2026, which Climb denies owing. This invoice followed Climb's successful dosing of its first patient in a Phase 2 clinical trial for budoprutug on November 17, 2025.
Dec 31, 2025, 9:12 PM
Climb Bio, Inc. enters exchange agreement with RA Capital Management
CLYM
Convertible Preferred Issuance
New Projects/Investments
- On December 11, 2025, Climb Bio, Inc. entered into an exchange agreement with RA Capital Management, L.P. and an affiliated entity.
- Pursuant to the agreement, the Exchanging Stockholder will exchange 20,440,000 shares of Climb Bio's Common Stock for a Pre-Funded Warrant to purchase an aggregate of 20,440,000 shares of Common Stock at an exercise price of $0.0001 per share.
- The transaction is expected to close on December 11, 2025, resulting in 47,744,435 shares of Common Stock issued and outstanding immediately afterward.
- Following the exchange, RA Capital and its affiliates will beneficially own Common Stock representing approximately 23.0% of the outstanding voting power, with a restriction preventing exercise of the warrant if it would result in beneficial ownership exceeding 33.0% of the outstanding Common Stock.
Dec 11, 2025, 1:16 PM
Climb Bio Outlines Key 2026 Milestones and Financial Position
CLYM
New Projects/Investments
Guidance Update
- Climb Bio (CLYM) anticipates significant data readouts in 2026 for its two clinical-stage monoclonal antibodies: budoprutug (CD19) and Climb 116 (anti-APRIL).
- For budoprutug, data from the subQ formulation in healthy volunteers is expected in the first half of 2026, with ITP and SLE data in the second half of 2026. A Phase 2 study is ongoing for membranous nephropathy (PMN), a lead program with a potential registrational endpoint of complete renal response in a 150-patient study.
- Climb 116, an anti-APRIL antibody for IgA nephropathy, is expected to have healthy volunteer data by mid-2026, which will include PK, PD, IgA suppression, and free/total APRIL levels. The company believes it has a potential best-in-class profile due to a longer half-life and a "sweeper mechanism".
- The company reported $176 million in cash at the end of Q3, providing a financial runway through 2027, extending beyond all 2026 data readouts.
Dec 2, 2025, 2:30 PM
Climb Bio Outlines 2026 Milestones for Autoimmune Disease Programs
CLYM
New Projects/Investments
Guidance Update
- Climb Bio anticipates significant clinical data readouts in 2026 for its two main assets: budoprutug (CD19 monoclonal antibody) and Climb 116 (anti-APRIL antibody).
- For budoprutug, data from the subcutaneous formulation in healthy volunteers is expected in the first half of 2026, while ITP and SLE data are anticipated in the second half of 2026. The lead program for budoprutug is in membranous nephropathy (PMN), a rare renal indication with no approved therapy, where a pivotal study would involve approximately 150 patients.
- For Climb 116, healthy volunteer data for IgA nephropathy is expected mid-2026, which will include pharmacokinetics (PK), pharmacodynamics (PD), and IgA suppression. This asset is differentiated by a longer half-life and a "sweeper mechanism" that degrades APRIL.
- The company reported $176 million in cash at the end of Q3, providing a runway through 2027, extending more than 12 months beyond all data readouts in 2026.
Dec 2, 2025, 2:30 PM
Climb Bio Reports Q3 2025 Financial Results and Provides Business Updates
CLYM
Earnings
Management Change
New Projects/Investments
- Climb Bio reported cash, cash equivalents and marketable securities of $175.8 million as of September 30, 2025, with a projected cash runway through 2027.
- For the third quarter ended September 30, 2025, Research and Development (R&D) expenses were $9.1 million and General and Administrative (G&A) expenses were $5.8 million, resulting in a net loss of $12.9 million or $0.19 per share.
- The company initiated the PrisMN Phase 2 trial of budoprutug in Primary Membranous Nephropathy (pMN) and a Phase 1 trial of budoprutug subcutaneous formulation. Regulatory clearance was also obtained to initiate the CLYM116 Phase 1 trial, with the first subject expected to be dosed by year-end 2025.
- Climb Bio strengthened its leadership team with the appointments of Susan Altschuller as Chief Financial Officer, Adam Villa as SVP, Technical Operations, and Ashley Jones as SVP, People & Workforce Strategy.
Nov 6, 2025, 12:15 PM
Climb Bio, Inc. Appoints New Chief Financial Officer and Amends Inducement Plan
CLYM
CFO Change
Executive Compensation
Management Change
- Susan Altschuller, Ph.D., MBA, was appointed as Chief Financial Officer and Treasurer of Climb Bio, Inc., effective October 1, 2025.
- Her compensation package includes an annual base salary of $510,000 and eligibility for an annual discretionary bonus of up to 40% of her base salary.
- She was also granted a stock option to purchase 600,000 shares of the company's common stock, vesting over approximately four years.
- The Board approved an amendment to the 2025 Inducement Plan, increasing the shares reserved for issuance from 1,250,000 to 2,000,000 shares.
- Cindy Driscoll ceased to serve as the principal financial officer but continues as the principal accounting officer.
Oct 1, 2025, 9:23 PM
Climb Bio Provides Pipeline Update and IgA Nephropathy Market Overview
CLYM
New Projects/Investments
Product Launch
Guidance Update
- Climb Bio expects to initiate Phase 1 for CLYM116 in IgA Nephropathy in Q4 2025 and anticipates initial Phase 1 data in mid-2026.
- The company also projects initial data for Budoprutug SC anti-CD19 in autoimmune disease in H1 2026.
- The target market for CLYM116, IgA Nephropathy, represents an estimated $10-20 billion opportunity in the US.
Sep 29, 2025, 12:00 PM
Climb Bio Provides Preclinical Data and Clinical Development Update for Climb 116
CLYM
New Projects/Investments
Guidance Update
- Climb Bio's newest candidate, Climb 116, a next-generation anti-APRIL sweeper antibody for IgA nephropathy, is expected to enter the clinic in Q4 this year. Preclinical data indicates a two to three times longer half-life and deeper, more durable IgA reductions (over 70% reduction) compared to first-generation anti-APRIL agents.
- Initial data from the Phase 1 trial for Climb 116 is anticipated mid-year 2026.
- The company's lead asset, BDO PROTEG, a B-cell-depleting DD19 monoclonal antibody, has four trials actively enrolling for systemic lupus erythematosus, immune thrombocytopenia, primary membranous nephropathy, and subcutaneous formulations.
Sep 29, 2025, 12:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more